menu
    • menu
    [{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Liquid","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Stallergenes Greer

    Menu

    Stallergenes Greer

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palforzia® Peanut Allergy Therapy Now Available in U.S. for Ages 1 to 3 Years

                            Details : Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Product Name : Palforzia

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 28, 2025

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Commission Approves Palforzia® for Toddlers with Peanut Allergy

                            Details : Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Product Name : Palforzia

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palforzia® Gets Positive CHMP Opinion for Peanut Allergy in Toddlers

                            Details : Palforzia is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Product Name : Palforzia

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Pediatric Indication Extension for Palforzia® Oral Immunotherapy

                            Details : Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Product Name : Palforzia

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 30, 2024

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch

                            Details : Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma

                            Product Name : Staloral Birch

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : Birch Pollen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allergen Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment ...

                            Details : Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only...

                            Product Name : Staloral

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 07, 2022

                            Lead Product(s) : Allergen Extract

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : House Dust Mite Allergen Extract

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stallergenes Greer Receives Market Approval in Austria for Its Sublingual Allergen Immunotherapy Tablet for Ho...

                            Details : The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.

                            Product Name : Actair

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 09, 2021

                            Lead Product(s) : House Dust Mite Allergen Extract

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth